R Cunill1, X Castells2, A Tobias3, D Capellà4. 1. Parc Sanitari Sant Joan de Déu, Fundació Sant Joan de Déu, Barcelona, Spain. 2. Clinical Pharmacology Unit, TransLab Research Group, Department of Medical Sciences, Universitat de Girona, Emili Grahit, 77, 17071, Girona, Spain. xavier.castells@udg.edu. 3. Institute of Environmental Assessment and Water Research (IDAEA), Spanish Council for Scientific Research (CSIC), Barcelona, Spain. 4. Clinical Pharmacology Unit, TransLab Research Group, Department of Medical Sciences, Universitat de Girona, Emili Grahit, 77, 17071, Girona, Spain.
Abstract
RATIONALE: The factors underlying the variability in the results of randomized, placebo-controlled clinical trials (RPCCT) assessing pharmacological interventions for adults with attention deficit hyperactivity disorder (ADHD) are not fully understood. METHODS: A systematic review and meta-analysis of RPCCT comparing pharmacological treatment and placebo in adults with ADHD was carried out. The study outcomes were all-cause treatment discontinuation, efficacy on ADHD symptoms, and safety. Patient-, intervention-, and study design-related covariates were collected. Meta-regression methods were applied. RESULTS: Forty-four studies involving 9952 patients were included. All-cause treatment discontinuation was slightly higher with pharmacological treatment than with placebo (odds ratio (OR) = 1.18; 95 % confidence interval (CI) 1.02, 1.36; p = 0.003). A better outcome on all-cause treatment discontinuation was observed in studies that provided concomitant psychotherapy when compared to those that did not (rate of OR (ROR) = 0.68, p = 0.048). Pharmacological treatment was efficacious for reducing ADHD symptoms (standardized mean difference (SMD) = 0.45; 95 % CI 0.37, 0.52; p < 0.00001), with stronger intervention effects found in studies investigating stimulant drugs (difference of SMD (Diff SMD) = 0.18, p = 0.017), in shorter studies (Diff SMD = -0.01, p = 0.044), and when clinician-rated scales were used (Diff SMD = 0.44, p < 0.0001). Pharmacological treatment was associated with more frequent adverse events (AEs) (OR = 2.29; 95 % CI 1.97, 2.66; p = 0.006). Studies with a lead-in phase and with a higher proportion of patients previously treated with stimulants were associated with a better safety outcome (ROR = 0.59, p = 0.017; ROR = 0.98, p = 0.036, respectively). CONCLUSION: Pharmacological treatment provides mild symptom improvement but is associated with frequent AEs and higher treatment discontinuation than placebo, particularly when no concomitant psychotherapy is administered. Stimulants appear more efficacious than non-stimulant drugs and the former should be preferred over the latter. The efficacy of pharmacological treatment should be monitored over time because it may decrease progressively.
RATIONALE: The factors underlying the variability in the results of randomized, placebo-controlled clinical trials (RPCCT) assessing pharmacological interventions for adults with attention deficit hyperactivity disorder (ADHD) are not fully understood. METHODS: A systematic review and meta-analysis of RPCCT comparing pharmacological treatment and placebo in adults with ADHD was carried out. The study outcomes were all-cause treatment discontinuation, efficacy on ADHD symptoms, and safety. Patient-, intervention-, and study design-related covariates were collected. Meta-regression methods were applied. RESULTS: Forty-four studies involving 9952 patients were included. All-cause treatment discontinuation was slightly higher with pharmacological treatment than with placebo (odds ratio (OR) = 1.18; 95 % confidence interval (CI) 1.02, 1.36; p = 0.003). A better outcome on all-cause treatment discontinuation was observed in studies that provided concomitant psychotherapy when compared to those that did not (rate of OR (ROR) = 0.68, p = 0.048). Pharmacological treatment was efficacious for reducing ADHD symptoms (standardized mean difference (SMD) = 0.45; 95 % CI 0.37, 0.52; p < 0.00001), with stronger intervention effects found in studies investigating stimulant drugs (difference of SMD (Diff SMD) = 0.18, p = 0.017), in shorter studies (Diff SMD = -0.01, p = 0.044), and when clinician-rated scales were used (Diff SMD = 0.44, p < 0.0001). Pharmacological treatment was associated with more frequent adverse events (AEs) (OR = 2.29; 95 % CI 1.97, 2.66; p = 0.006). Studies with a lead-in phase and with a higher proportion of patients previously treated with stimulants were associated with a better safety outcome (ROR = 0.59, p = 0.017; ROR = 0.98, p = 0.036, respectively). CONCLUSION: Pharmacological treatment provides mild symptom improvement but is associated with frequent AEs and higher treatment discontinuation than placebo, particularly when no concomitant psychotherapy is administered. Stimulants appear more efficacious than non-stimulant drugs and the former should be preferred over the latter. The efficacy of pharmacological treatment should be monitored over time because it may decrease progressively.
Authors: Guilherme V Polanczyk; Giovanni A Salum; Luisa S Sugaya; Arthur Caye; Luis A Rohde Journal: J Child Psychol Psychiatry Date: 2015-02-03 Impact factor: 8.982
Authors: Agnes Dechartres; Isabelle Boutron; Ludovic Trinquart; Pierre Charles; Philippe Ravaud Journal: Ann Intern Med Date: 2011-07-05 Impact factor: 25.391
Authors: Frances R Levin; Suzette M Evans; Daniel J Brooks; Aparna S Kalbag; Fatima Garawi; Edward V Nunes Journal: Drug Alcohol Depend Date: 2005-08-15 Impact factor: 4.492
Authors: Narong Maneeton; Benchalak Maneeton; Sirijit Suttajit; Jirayu Reungyos; Manit Srisurapanont; Stephen D Martin Journal: Drug Des Devel Ther Date: 2014-10-03 Impact factor: 4.162
Authors: Samuel J Westwood; Natali Bozhilova; Marion Criaud; Sheut-Ling Lam; Steve Lukito; Sophie Wallace-Hanlon; Olivia S Kowalczyk; Afroditi Kostara; Joseph Mathew; Bruce E Wexler; Roi Cohen Kadosh; Philip Asherson; Katya Rubia Journal: IBRO Neurosci Rep Date: 2021-12-24
Authors: Analucia A Alegria; Melanie Wulff; Helen Brinson; Gareth J Barker; Luke J Norman; Daniel Brandeis; Daniel Stahl; Anthony S David; Eric Taylor; Vincent Giampietro; Katya Rubia Journal: Hum Brain Mapp Date: 2017-03-25 Impact factor: 5.038
Authors: Carlos López-Pinar; Sonia Martínez-Sanchís; Enrique Carbonell-Vayá; Javier Fenollar-Cortés; Julio Sánchez-Meca Journal: Front Psychol Date: 2018-05-04